Louis P Garrison
Louis P Garrison
Professor Emeritus, University of Washington
Verified email at uw.edu
Title
Cited by
Cited by
Year
Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers
JJ Carlson, SD Sullivan, LP Garrison, PJ Neumann, DL Veenstra
Health policy 96 (3), 179-190, 2010
2772010
Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial
J Cassidy, JY Douillard, C Twelves, JJ McKendrick, W Scheithauer, ...
British journal of cancer 94 (8), 1122-1129, 2006
1372006
Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial
J Cassidy, JY Douillard, C Twelves, JJ McKendrick, W Scheithauer, ...
British journal of cancer 94 (8), 1122-1129, 2006
1372006
Can’t get no satisfaction? Will pay for performance help?
A Towse, LP Garrison
Pharmacoeconomics 28 (2), 93-102, 2010
1202010
Challenges in the development and reimbursement of personalized medicine—payer and manufacturer perspectives and implications for health economics and outcomes research: a …
E Faulkner, L Annemans, L Garrison, M Helfand, AP Holtorf, J Hornberger, ...
Value in Health 15 (8), 1162-1171, 2012
1172012
Global eradication of measles: an epidemiologic and economic evaluation
A Levin, C Burgess, LP Garrison, C Bauch, J Babigumira, E Simons, ...
The Journal of infectious diseases 204 (suppl_1), S98-S106, 2011
832011
Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force Report—Part I
JW Hay, J Smeeding, NV Carroll, M Drummond, LP Garrison, EC Mansley, ...
Value in Health 13 (1), 3-7, 2010
822010
The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR‐Tyrosine Kinase Inhibitor Therapy in Non–Small‐Cell Lung Cancer
JJ Carlson, LP Garrison, SD Ramsey, DL Veenstra
Value in Health 12 (1), 20-27, 2009
822009
Estimating the effect of changes in body mass index on health state preferences
Z Hakim, A Wolf, LP Garrison
Pharmacoeconomics 20 (6), 393-404, 2002
812002
A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice
DL Veenstra, JA Roth, LP Garrison, SD Ramsey, W Burke
Genetics in Medicine 12 (11), 686-693, 2010
782010
The use, safety and cost of bariatric surgery before and after Medicare’s national coverage decision
DR Flum, S Kwon, K MacLeod, B Wang, R Alfonso-Cristancho, ...
Annals of surgery 254 (6), 860, 2011
742011
Cost-effectiveness of bariatric surgical procedures for the treatment of severe obesity
BCM Wang, ES Wong, R Alfonso-Cristancho, H He, DR Flum, ...
The European Journal of Health Economics 15 (3), 253-263, 2014
692014
Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks …
JH Best, RR Rubin, M Peyrot, Y Li, P Yan, J Malloy, LP Garrison
Diabetes Care 34 (2), 314-319, 2011
582011
The drug budget silo mentality in Europe: an overview
L Garrison, A Towse
Value in Health 6, S1-S9, 2003
542003
Cost effectiveness of a pharmacy-only refill program in a large urban HIV/AIDS clinic in Uganda
JB Babigumira, B Castelnuovo, A Stergachis, A Kiragga, P Shaefer, ...
PLoS One 6 (3), e18193, 2011
522011
Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers
JJ Carlson, KS Gries, K Yeung, SD Sullivan, LP Garrison
Applied health economics and health policy 12 (3), 231-238, 2014
512014
Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda
JB Babigumira, B Castelnuovo, M Lamorde, A Kambugu, A Stergachis, ...
BMC Health Services Research 9 (1), 1-6, 2009
512009
The cost effectiveness of mycophenolate mofetil in the first year after primary cadaveric transplant. US Renal Transplant Mycophenolate Mofetil Study Group.
SD Sullivan, LP Garrison, JH Best
Journal of the American Society of Nephrology 8 (10), 1592-1598, 1997
511997
Performance-based risk-sharing arrangements: an updated international review
JJ Carlson, S Chen, LP Garrison
Pharmacoeconomics 35 (10), 1063-1072, 2017
482017
Strategic use of pharmacoeconomic research in early drug development and global pricing
K Clemens, LP Garrison, A Jones, F Macdonald
Pharmacoeconomics 4 (5), 315-322, 1993
481993
The system can't perform the operation now. Try again later.
Articles 1–20